Overview

* Lisata Q3 net loss narrows to $4.2 mln from $4.9 mln yr/yr

* Operating expenses decreased by 17.3% to $4.4 mln in Q3 2025

* Cash runway extended into Q1 2027

Outlook

* Company projects cash reserves will fund operations into Q1 2027

Result Drivers

* CASH RUNWAY EXTENSION - Cash reserves expected to fund operations into Q1 2027, with no debt

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.49

Q3 Net -$4.25

Income mln

Q3 $4.41

Operatin mln

g

Expenses

Q3 -$4.41

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Lisata Therapeutics Inc ( LSTA ) is $15.00, about 84.4% above its November 5 closing price of $2.34

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)